Literature DB >> 12839562

Sustained activation of fibroblast transforming growth factor-beta/Smad signaling in a murine model of scleroderma.

Shinsuke Takagawa1, Gabriella Lakos, Yasuji Mori, Toshiyuki Yamamoto, Kiyoshi Nishioka, John Varga.   

Abstract

Transforming growth factor-beta is responsible for triggering a cascade of events leading to fibrosis in scleroderma. The Smads are intracellular signal transducers recently shown to mediate fibroblast activation and other profibrotic responses elicited by transforming growth factor-betain vitro. To understand better the involvement of Smads in the pathogenesis of fibrosis, we examined Smad expression and activation in situ in a murine model of scleroderma. Bleomycin injections induced striking dermal infiltration with macrophages by 3 d, and progressive fibrosis by 2 wk. Infiltrating macrophages and resident fibroblasts expressed Smad3, the positive mediator for transforming growth factor-beta responses. Importantly, in bleomycin-injected skin, fibroblasts showed predominantly nuclear localization of Smad3 and intense staining for phospho-Smad2/3. Furthermore, phosphorylated Smad2/3 in fibroblasts was detected even after the resolution of inflammation. Expression of Smad7, the endogenous inhibitor of transforming growth factor-beta/Smad signaling, was strongly induced in dermal cells by transforming growth factor-beta, but not by bleomycin injections. Collectively, these results indicate that bleomycin-induced murine scleroderma is associated with rapid and sustained induction of transforming growth factor-beta/Smad signaling in resident dermal fibroblasts. Despite apparent activation of the intracellular transforming growth factor-beta signaling pathway in the lesional dermis, the expression of transforming growth factor-beta-inducible Smad7 was not upregulated. In light of the critical function of Smad7 as an endogenous inhibitor of Smad signaling that restricts the duration and magnitude of transforming growth factor-beta responses, and as a mediator of apoptosis, relative Smad7 deficiency observed in the present studies may account for sustained activation of transforming growth factor-beta/Smad signaling in lesional tissues. These findings raise the possibility that Smads plays an important part in the pathogenesis of fibrosis, and may therefore represent targets for selective anti-fibrotic interventions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12839562     DOI: 10.1046/j.1523-1747.2003.12308.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  41 in total

1.  The early growth response gene Egr2 (Alias Krox20) is a novel transcriptional target of transforming growth factor-β that is up-regulated in systemic sclerosis and mediates profibrotic responses.

Authors:  Feng Fang; Kohtaro Ooka; Swati Bhattacharyya; Swati Bhattachyya; Jun Wei; Minghua Wu; Pan Du; Simon Lin; Francesco Del Galdo; Carol A Feghali-Bostwick; John Varga
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  Nimbolide ameliorates fibrosis and inflammation in experimental murine model of bleomycin-induced scleroderma.

Authors:  Snehalatha Diddi; Swarna Bale; Gauthami Pulivendala; Chandraiah Godugu
Journal:  Inflammopharmacology       Date:  2018-09-14       Impact factor: 4.473

3.  Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma?

Authors:  Jun Wei; Denisa Melichian; Kazuhiro Komura; Monique Hinchcliff; Anna P Lam; Robert Lafyatis; Cara J Gottardi; Ormond A MacDougald; John Varga
Journal:  Arthritis Rheum       Date:  2011-06

4.  Hyaluronan synthase 2 protects skin fibroblasts against apoptosis induced by environmental stress.

Authors:  Yan Wang; Mark E Lauer; Sanjay Anand; Judith A Mack; Edward V Maytin
Journal:  J Biol Chem       Date:  2014-09-29       Impact factor: 5.157

Review 5.  Pathogenesis of systemic sclerosis-current concept and emerging treatments.

Authors:  Masutaka Furue; Chikage Mitoma; Hiroki Mitoma; Gaku Tsuji; Takahito Chiba; Takeshi Nakahara; Hiroshi Uchi; Takafumi Kadono
Journal:  Immunol Res       Date:  2017-08       Impact factor: 2.829

6.  Thyroid hormones inhibit TGF-β signaling and attenuate fibrotic responses.

Authors:  Elvira Alonso-Merino; Rosa Martín Orozco; Lidia Ruíz-Llorente; Olaia A Martínez-Iglesias; Juan Pedro Velasco-Martín; Ana Montero-Pedrazuela; Luisa Fanjul-Rodríguez; Constanza Contreras-Jurado; Javier Regadera; Ana Aranda
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-31       Impact factor: 11.205

7.  Identification of cadherin 11 as a mediator of dermal fibrosis and possible role in systemic sclerosis.

Authors:  Minghua Wu; Mesias Pedroza; Robert Lafyatis; Anuh-Teresa George; Maureen D Mayes; Shervin Assassi; Filemon K Tan; Michael B Brenner; Sandeep K Agarwal
Journal:  Arthritis Rheumatol       Date:  2014-04       Impact factor: 10.995

8.  Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma.

Authors:  Minghua Wu; Denisa S Melichian; Eric Chang; Matthew Warner-Blankenship; Asish K Ghosh; John Varga
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

9.  Connective tissue growth factor/CCN2-null mouse embryonic fibroblasts retain intact transforming growth factor-beta responsiveness.

Authors:  Yasuji Mori; Monique Hinchcliff; Minghua Wu; Matthew Warner-Blankenship; Karen M Lyons; John Varga
Journal:  Exp Cell Res       Date:  2007-12-23       Impact factor: 3.905

10.  Liver fibrosis secondary to bile duct injury: correlation of Smad7 with TGF-beta and extracellular matrix proteins.

Authors:  María del Pilar Alatorre-Carranza; Alejandra Miranda-Díaz; Irinea Yañez-Sánchez; Oscar Pizano-Martínez; José M Hermosillo-Sandoval; Mónica Vázquez-Del Mercado; Sebastián Hernández-Hoyos; Ricardo Martínez-Abundis; Mary Fafutis-Morris; Jorge Segura-Ortega; Vidal Delgado-Rizo
Journal:  BMC Gastroenterol       Date:  2009-10-31       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.